Skip to main content

Table 1 A summary of immunohistochemical analysis of MEK1/2 and its phosphorylation at Ser217/221 in human HCC. Human HCCs (T) and adjacent benign liver (ABL) tissues (N) were collected, paraffin blocks were prepared and immunohistochemical analysis was performed as described under Experimental Procedures. Tissue sections were stained with anti-phospho-MEK1/2 (Ser217/221) antibody. Only nuclear immunoreactivity was considered positive. Sections were scored as 1 (<1.0% of tumor cells positive); 2 (1–5% of tumor cells positive); 3 (5–10% of tumor cells positive) and 4 (>10% of tumor cells positive).

From: Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis

Genes examined Normal adjacent Liver tissues (n = 46) HCC Tumours (n = 46)
   Stages
   I II III IV
   (n = 4) (n = 25) (n = 11) (n = 6)
MEK 1/2 46/46 (100%) 4/4 (100%) 25/25 (100%) 11/11 (100%) 6/6 (100%)
Phosphorylated MEK 1/2 Score (% of positive cells) 0/0 (0%)     
1 (< 1.0) 0 2/4 (50%) 20/25 (80%) 4/11 (36.36%) 1/6 (16.67%)
2 (1 – 5) 0 - 4/25 (16%) 4/11 (36/36%) -
3 (5 – 10) 0 1/4 (25%) 1/25 (4%) 1/11 (9.09%) 3/6 (50%)
4 (>10) 0 1/4 (25%) - 2/11 (18.19%) 2/6 (33.33%)